Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies

Historically, the prognosis for patients who have melanoma brain metastasis (MBM) has been dismal. However, breakthroughs in targeted and immunotherapies have improved long‐term survival in those with advanced melanoma. Therefore, MBM presentation, prognosis, and the use of multimodality central nervous system (CNS)‐directed treatment were reassessed.

• Publication year

  2021

• Venue

  Cancer

• Publication date

  2021-03-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.33459PMID 33651913PMCID PMC9275782
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases

  2019cited by this paper
• Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis

  2019cited by this paper
• Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti–PD‐1 in patients with metastatic melanoma

  2019cited by this paper
• Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

  2019cited by this paper
• Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD)

  2019cited by this paper
• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

  2019cited by this paper
• Changing the standard of care for treating melanoma brain metastases.

  2018cited by this paper
• Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

  2018cited by this paper
• Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

  2018cited by this paper
• Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

  2018cited by this paper
• Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort

  2018cited by this paper
• Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2

  2018cited by this paper
• Using immunotherapy to boost the abscopal effect

  2018cited by this paper
• Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation

  2018cited by this paper
• Melanoma Brain Metastases: Current Areas of Investigation and Future Directions.

  2017cited by this paper
• Metastatic melanoma: prognostic factors and survival in patients with brain metastases

  2017cited by this paper
• Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

  2017cited by this paper
• Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).

  2017cited by this paper
• Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer

  2017cited by this paper
• Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.

  2017cited by this paper
• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  2017cited by this paper
• Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.

  2016cited by this paper
• Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.

  2016cited by this paper
• Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

  2016cited by this paper
• Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy

  2016cited by this paper
• Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

  2016cited by this paper
• Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.

  2016cited by this paper
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

  2015cited by this paper
• Improved overall survival in melanoma with combined dabrafenib and trametinib.

  2015cited by this paper
• Systemic treatments for metastatic cutaneous melanoma.

  2014cited by this paper
• Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.

  2014cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.

  2012cited by this paper
• Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

  2012cited by this paper
• Prognostic factors for survival in melanoma patients with brain metastases

  2011cited by this paper
• Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.

  2011cited by this paper
• Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

  2010cited by this paper
• Brain metastases admissions in Sweden between 1987 and 2006

  2009cited by this paper
• Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

  2009cited by this paper
• Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

  2008cited by this paper
• Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features.

  2008cited by this paper
• Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.

  2004cited by this paper
• Determinants of outcome in melanoma patients with cerebral metastases.

  2004cited by this paper
• Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma

  2002cited by this paper
• Systemic treatments for metastatic cutaneous melanoma.

  2000cited by this paper
• Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

  1998cited by this paper
• A randomized trial of surgery in the treatment of single metastases to the brain.

  1990cited by this paper

• The Effect of Concomitant Immunotherapy and Stereotactic Radiotherapy, and of Location on Survival in Patients With Brain Metastases From Melanoma

  2025cites this paper
• Persistent Altered Sensorium in a Patient Presenting With Acute Metabolic Encephalopathy From Diabetic Ketoacidosis and Metastatic Recurrent Melanoma of the Lung and Brain

  2025cites this paper
• Tumor Microenvironment in Melanoma Brain Metastasis: A New Potential Target?

  2025cites this paper
• Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment

  2025cites this paper
• Practice Variation in Perioperative Dexamethasone Use and Outcomes in Brain Metastasis Resection

  2025cites this paper
• Spatial-demographic analysis model for brain metastases distribution

  2025cites this paper
• Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022).

  2025cites this paper
• A Melanoma Brain Metastasis CTC Signature and CTC:B-cell Clusters Associate with Secondary Liver Metastasis: A Melanoma Brain–Liver Metastasis Axis

  2025cites this paper
• Prognostic factors of brain metastases affecting survival: an Indonesian cohort

  2025cites this paper
• Impact of immunotherapy on outcomes of cutaneous melanoma and concurrent brain metastasis: a surveillance, epidemiology, and end results analysis of 2010-2020.

  2025cites this paper
• Multidisciplinary review outperforms qualitative MR perfusion in distinguishing post-radiation brain metastasis recurrence versus radionecrosis

  2025cites this paper
• Intrathecal pemetrexed in patients with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistant refractory leptomeningeal metastasis lung adenocarcinoma: a retrospective study

  2025cites this paper
• Single-cell transcriptome analysis suggests cells of the tumor microenvironment as a major discriminator between brain and extracranial melanoma metastases

  2025cites this paper
• Treatment patterns and outcomes in melanoma brain metastasis: exploring immune-related adverse events and survival.

  2025cites this paper
• Melanoma GPA as a novel prognostic scoring model based on initial brain metastasis velocity

  2025cites this paper
• Non-destructive luminescence and PET imaging to monitor tissue microenvironment in microphysiological systems during brain metastasis using dissociated cerebral organoids

  2025cites this paper
• Unusual pineal gland lesion presenting with obstructive hydrocephalus: A multimodal imaging perspective

  2025cites this paper
• Melanoma Brain Metastasis: Biology and Therapeutic Advances.

  2024cites this paper
• IMMUNE AND MOLECULAR CORRELATES OF RESPONSE TO IMMUNOTHERAPY REVEALED BY BRAIN-METASTATIC MELANOMA MODELS

  2024cites this paper
• “Symptomatic” melanoma brain metastases: A call for clear definitions and adoption of standardized tools

  2024cites this paper
• Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy

  2024cites this paper
• Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery

  2024cites this paper
• Demographics aspects of brain and spine metastatic melanoma. Retrospective analysis in a single third-level center

  2024cites this paper
• Upregulation of HLA‐II related to LAG‐3+CD4+ T cell infiltration is associated with patient outcome in human glioblastoma

  2024cites this paper
• Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy

  2024cites this paper
• Antipsychotic Zuclopenthixol Inhibits Melanoma Growth and Brain Metastasis by Inducing Apoptosis and Cell Cycle Arrest.

  2024cites this paper
• Symptomatic brain metastases in melanoma

  2024cites this paper
• Enrollment Trends Among Patients with Melanoma Brain Metastasis in Active Clinical Trials

  2024cites this paper
• Prevention of Brain Metastases: A New Frontier

  2024cites this paper
• Factors associated with the use of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease: A SEER-Medicare study.

  2024cites this paper
• Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS

  2023influential citation
• Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure

  2023cites this paper
• Impact of Novel Treatments in Patients with Melanoma Brain Metastasis: Real-World Data

  2023cites this paper
• Melanoma Brain Metastases: A Retrospective Analysis of Prognostic Factors and Efficacy of Multimodal Therapies

  2023cites this paper
• Neuronal Cannabinoid CB1 Receptors Suppress the Growth of Melanoma Brain Metastases by Inhibiting Glutamatergic Signalling

  2023cites this paper
• Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy.

  2023cites this paper
• A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

  2023cites this paper
• Diagnostic and Therapeutic Updates in Leptomeningeal Disease

  2023cites this paper
• Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape

  2023cites this paper
• Brain metastasis screening in the molecular age

  2023cites this paper
• The longitudinal risk of hemorrhage of melanoma brain metastases after Gamma Knife radiosurgery.

  2023cites this paper
• Outcomes Following Early Postoperative Adjuvant Radiosurgery for Brain Metastases

  2023cites this paper
• Peripheral macrophages in the development and progression of structural cerebrovascular pathologies

  2023cites this paper
• A single‐center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan

  2023cites this paper
• Central Nervous System Melanoma: Report of two cases

  2023cites this paper
• Real-world data on melanoma brain metastases and survival outcome

  2022cites this paper
• Decoding molecular programs in melanoma brain metastases

  2022cites this paper
• The Analysis of Trends in Survival for Patients with Melanoma Brain Metastases with Introduction of Novel Therapeutic Options before the Era of Combined Immunotherapy—Multicenter Italian–Polish Report

  2022cites this paper
• Radiosurgery fractionation and post-treatment hemorrhage development for intact melanoma brain metastases.

  2022cites this paper
• Longest survival with primary intracranial malignant melanoma: A case report and literature review

  2022cites this paper
• Molecular Mechanisms Driving the Formation of Brain Metastases

  2022cites this paper
• Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities

  2022cites this paper
• Fatal subarachnoid hemorrhage after ventriculoperitoneal shunt placement to manage communicating hydrocephalus due to melanoma leptomeningeal disease

  2022cites this paper
• Changes in outcomes and factors associated with survival in melanoma patients with brain metastases

  2022cites this paper
• Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma brain metastasis.

  2022cites this paper
• A Conceptual Framework for Inducing T Cell-Mediated Immunity Against Glioblastoma

  2022cites this paper
• Effectiveness of Immune Checkpoint Inhibition vs Chemotherapy in Combination With Radiation Therapy Among Patients With Non–Small Cell Lung Cancer and Brain Metastasis Undergoing Neurosurgical Resection

  2022cites this paper
• Epidemiology of Brain Metastases and Leptomeningeal Disease.

  2021cites this paper
• Case report of a rare primary intracranial malignant melanoma, reviewing the literature and guidance for management

  2021cites this paper
• Multimodality durable salvage of recurrent brain metastases refractory to LITT, SRS and immunotherapy with resection and cesium-131 brachytherapy: case report and literature review

  2021cites this paper
• Salvage surgery for local control of brain metastases after prior stereotactic radiosurgery: a single-center series.

  2021cites this paper
• Salvage resection of recurrent previously irradiated brain metastases: tumor control and radiation necrosis dependency on adjuvant re-irradiation

  2021cites this paper
• Outcomes Following Hypofractionated Stereotactic Radiotherapy to the Cavity After Surgery for Melanoma Brain Metastases.

  2021cites this paper
• Risk of tract recurrence with stereotactic biopsy of brain metastases: an 18-year cancer center experience.

  2021cites this paper
• Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes

  2021cites this paper
• The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes

  2021cites this paper
• Brain Metastases: An Update on Multi-disciplinary Approach of Clinical Management.

  2021cites this paper